More Americans are choosing GLP-1 weight loss injections over bariatric surgery than ever before. Prescriptions for drugs like Ozempic and Wegovy climbed 24% between 2018 and 2025, while bariatric surgery rates fell to half their 2022 peak, according to a new study. The shift is real, but doctors say the reasons behind it are more complicated than simple patient preference.
Insurance coverage is often the deciding factor. In states like Louisiana, patients are more likely to have bariatric surgery covered than GLP-1 medications. That matters because GLP-1 drugs are designed to be taken long-term, sometimes for life, which means the total cost can exceed a one-time surgical procedure. Here in Florida, coverage varies widely depending on your plan, so it’s worth calling your insurer before assuming anything.
The most important takeaway? There is no single right answer. One patient, Emily Showalter, lost nearly 100 pounds on injections. Another, Blake Davenport, found success only after bariatric surgery, losing 135 pounds. Meanwhile, researchers found nearly 95% of patients with severe obesity receive no treatment at all. As Dr. Shauna Levy of Tulane’s Weight Loss Center puts it, obesity is a disease that deserves medical treatment, not judgment. If you’re weighing your options, talk to your doctor, check your coverage, and ignore the stigma. Have you or someone you love explored either path? Share your story with us.
